Hydrochlorothiazide And Valsartan

Introduction Overview

Generic Name

hydrochlorothiazide and valsartan

Brand Name

Diovan HCT

Dosage Form

oral tablet (12.5 mg-160 mg; 12.5 mg-320 mg; 12.5 mg-80 mg; 25 mg-160 mg; 25 mg-320 mg)

Drug Class

Angiotensin II inhibitors with thiazides

Pharmacokinetics

Absorption:
Hydrochlorothiazide and valsartan are administered orally as a combined tablet. Valsartan achieves peak plasma concentrations approximately 2 to 4 hours after oral dosing, with an absolute bioavailability of about 23%. Hydrochlorothiazide shows rapid absorption with peak plasma levels usually within 2 hours post-administration. Food effects can reduce the bioavailability of valsartan but have minor clinical relevance. The combination allows for enhanced antihypertensive efficacy due to the complementary mechanisms of both agents.

Distribution:
Valsartan exhibits moderate plasma protein binding of approximately 95%, primarily to serum albumin, facilitating a relatively low volume of distribution (around 17 liters). Hydrochlorothiazide binds to plasma proteins to a lesser extent, roughly 40% to 68%, and distributes extensively throughout body tissues and fluid compartments. Both drugs cross the placental barrier but have limited or no penetration into breast milk in clinically significant amounts. The combined distribution profiles support a synergistic effect on vascular resistance and volume status.

Metabolism:
Valsartan undergoes minimal hepatic metabolism, primarily via glucuronidation into inactive metabolites, with less than 20% being metabolized. Hydrochlorothiazide is not metabolized and is excreted unchanged via the kidneys. The minimal metabolism of valsartan decreases the risk of drug-drug interactions related to cytochrome P450 enzymes, making the combination favorable in patients needing polypharmacy.

Elimination:
Valsartan is eliminated predominantly through biliary excretion, with approximately 83% excreted in feces and about 13% in urine. The elimination half-life of valsartan ranges between 6 and 9 hours. Hydrochlorothiazide is eliminated primarily by renal excretion unchanged, with an elimination half-life of approximately 6 to 15 hours depending on renal function. Renal impairment can prolong hydrochlorothiazide elimination leading to accumulation, requiring dose adjustment. The combined elimination pathways emphasize the necessity for careful monitoring in hepatic or renal dysfunction.

Dosage Forms

Available Dosage Forms:
The combination of hydrochlorothiazide and valsartan is formulated as oral tablets with the following specific dosages enumerated:
- 12.5 mg hydrochlorothiazide - 80 mg valsartan
- 12.5 mg hydrochlorothiazide - 160 mg valsartan
- 12.5 mg hydrochlorothiazide - 320 mg valsartan
- 25 mg hydrochlorothiazide - 160 mg valsartan
- 25 mg hydrochlorothiazide - 320 mg valsartan
This range allows for flexible titration of antihypertensive therapy tailored to individual patient response.

Dosages for Adults and Adolescents:
The usual adult starting dose for the treatment of hypertension is one tablet containing 12.5 mg hydrochlorothiazide and 160 mg valsartan once daily. Dose titration may be performed every one to two weeks based on blood pressure response and tolerability, with a maximum recommended dose of 25 mg hydrochlorothiazide and 320 mg valsartan daily. The combination is not approved for pediatric use (<18 years).

Specific Patient Populations:
Dose adjustments or cautious use are advised in patients with renal impairment, particularly moderate to severe cases, due to the renal elimination of hydrochlorothiazide. In hepatic impairment, valsartan's exposure may increase; hence, dosage should be carefully considered. The combination is contraindicated in pregnancy due to potential fetal toxicity. Elderly patients may require close monitoring for volume depletion and electrolyte abnormalities. No dosage adjustment is typically needed based on age alone, but clinical judgment should prevail.

Mechanism Of Action

Hydrochlorothiazide and valsartan together exert synergistic antihypertensive effects through distinct but complementary molecular mechanisms. Hydrochlorothiazide is a thiazide diuretic that primarily inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron. This inhibition decreases sodium and chloride reabsorption, increasing their excretion—resulting in osmotic diuresis and reduction of plasma volume. The consequent decrease in extracellular fluid volume lowers cardiac output initially and, with chronic use, reduces peripheral vascular resistance, contributing to sustained blood pressure reduction.

Valsartan acts as a selective angiotensin II type 1 (AT1) receptor antagonist. By blocking the binding of angiotensin II to AT1 receptors on vascular smooth muscle and aldosterone-secreting cells, valsartan inhibits vasoconstriction and aldosterone release. This blockade reduces peripheral vascular resistance and sodium and water retention, complementing the diuretic effect of hydrochlorothiazide. This dual blockade leads to enhanced blood pressure control without some of the compensatory mechanisms, such as reflex tachycardia that can occur with other antihypertensives.

At the cellular level, valsartan prevents angiotensin II-induced activation of intracellular signaling pathways that promote vasoconstriction, oxidative stress, inflammation, and cellular hypertrophy. This contributes not only to blood pressure lowering but also to potential cardiovascular and renal protective effects, including reduced remodeling and fibrosis in target organs. Hydrochlorothiazide further modulates ion transport in the kidney, influencing electrolyte balance and vascular smooth muscle sensitivity.

Compared to other ARBs or thiazide diuretics alone, the combination of valsartan with hydrochlorothiazide has been shown in clinical studies to produce additive antihypertensive effects, improve patient compliance, and reduce side effects associated with higher doses of individual agents. Research supports this combination's efficacy in patients who have insufficient control with monotherapy, highlighting its role in multidrug regimens for resistant hypertension.

Pharmacological Actions

Thiazide diuretic effect: inhibits sodium-chloride symporter in distal convoluted tubule leading to natriuresis and diuresis
Angiotensin II receptor antagonist action: blocks AT1 receptors causing vasodilation and decreased aldosterone secretion
Reduction in plasma volume resulting in decreased cardiac output
Decreased peripheral vascular resistance contributing to sustained blood pressure lowering
Inhibition of angiotensin II-mediated cellular proliferation and vascular remodeling
Modulation of electrolyte balance through increased renal excretion of sodium and chloride
Prevention of aldosterone-induced sodium and water retention
Potential renal protection by reducing intraglomerular pressure and proteinuria
Improved cardiovascular outcomes through combined vascular and volume effects
Complementary mechanism reducing compensatory sodium retention due to ACE system blockade
Reduction in systemic oxidative stress and inflammation associated with hypertension
Enhancement of antihypertensive efficacy in patients unresponsive to monotherapy
Synergistic effect allowing for lower doses and reduced adverse effects
No significant impact on heart rate due to selective receptor blockade

Therapeutic Or Clinical Uses

Treatment of essential hypertension in adults who require combination therapy
Management of patients with hypertension inadequately controlled by monotherapy with either valsartan or hydrochlorothiazide
Reduction of risk of stroke, myocardial infarction, and cardiovascular mortality associated with high blood pressure
Off-label use as adjunct therapy in resistant hypertension
Use in hypertensive patients with concomitant conditions such as left ventricular hypertrophy or diabetic nephropathy (under clinical discretion)
Treatment option for patients intolerant to other antihypertensive drug classes
Combination therapy to improve patient compliance through fixed-dose formulation
Management of fluid retention in hypertensive patients through diuretic effect
Stabilization of blood pressure in patients with cardiovascular risk factors
Facilitation of renal protective strategies in hypertensive nephropathy

Side Or Adverse Effects

Dizziness and light-headedness, especially upon standing due to blood pressure lowering
Headache, possibly related to vasodilation and blood pressure changes
Cold-like symptoms such as stuffy nose, sneezing, and sore throat
Electrolyte imbalances, including hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia
Signs of electrolyte disturbance such as muscle pain, weakness, confusion, and irregular heartbeat
Renal impairment manifesting as decreased urine output, swelling, or worsening kidney function
Hypotension with symptoms of fainting, especially after initiating therapy or dose escalation
Hyperuricemia potentially triggering gout attacks
Photosensitivity reactions increasing the risk of skin cancer upon UV exposure
Allergic reactions including rash, pruritus, or angioedema
Possible hepatic effects including jaundice and elevated liver enzymes
Rare risk of rhabdomyolysis characterized by unexplained muscle pain and dark urine
Abdominal discomfort or gastrointestinal disturbances
Fatigue and weakness related to hypotensive or electrolyte effects
Potential increase in blood glucose levels or masked hypoglycemia in diabetic patients

Precautions

Avoid use in patients with known hypersensitivity to valsartan, hydrochlorothiazide, or sulfa drugs
Monitor renal function and electrolytes regularly, especially in patients with kidney disease or diabetes
Use cautiously in patients with hepatic impairment or cholestasis
Assess for signs of fluid or electrolyte imbalance during therapy
Avoid concomitant use with aliskiren in patients with diabetes or renal impairment due to increased risk of adverse effects
Educate patients to avoid sudden position changes to prevent orthostatic hypotension
Advise the use of sunscreen and protective clothing due to increased risk of photosensitivity and skin cancer
Avoid potassium-containing salt substitutes or supplements unless prescribed
Cautious use in elderly patients due to increased susceptibility to volume depletion and orthostatic hypotension
Monitor blood pressure regularly and adjust doses accordingly
Screen for gout history as hydrochlorothiazide can elevate uric acid levels
Use during pregnancy is contraindicated due to risk of fetal toxicity
Contraindicated in patients unable to urinate or with severe renal impairment
Adjust dose or discontinue prior to surgery to manage blood pressure and fluid balance
Avoid breastfeeding during treatment due to potential drug excretion in milk

Warnings

Do not use if pregnant; valsartan may cause fetal injury or death especially in the second and third trimesters
Avoid use if allergic to sulfa drugs or valsartan
Discontinue if signs of angioedema, severe allergic reactions, or hypersensitivity develop
Monitor for symptoms of electrolyte imbalance such as muscle weakness, dizziness, or irregular heartbeat
Risk of acute kidney injury in patients with impaired renal function or dehydration
May cause hypotension and syncope, particularly after the first dose or dose escalation
Potential risk of hyperkalemia especially when combined with other agents that increase potassium
Hydrochlorothiazide can increase photosensitivity and risk of non-melanoma skin cancer with prolonged exposure
Use caution in patients with heart failure or volume depletion
Not indicated for use in children under 18 years
Avoid concomitant use with aliskiren in patients with diabetes or kidney disease due to risk of adverse outcomes
Risk of severe allergic reactions including Stevens-Johnson syndrome (rare)
May impair glycemic control in diabetic patients requiring adjustment of antidiabetic therapy
Adjust or stop therapy if jaundice or liver dysfunction is detected
Discontinue or adjust dose when symptoms of dehydration, vomiting, or diarrhea occur to prevent severe hypotension

Contraindication

Known hypersensitivity or allergy to valsartan
Known hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs
Patients unable to produce urine (anuria)
Pregnancy due to risk of fetal injury or death
Concurrent use with aliskiren in patients with diabetes or renal impairment
Severe hepatic impairment or biliary obstruction in some cases
History of angioedema related to previous treatment with angiotensin receptor blockers or ACE inhibitors
Patients with severe electrolyte imbalances that are uncorrected
Use in pediatric patients less than 18 years of age
Known hypersensitivity to any component of the combination formulation

Drug Interactions

Potassium supplements or potassium-sparing diuretics may increase hyperkalemia risk
Nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen and naproxen may reduce antihypertensive effect and increase renal toxicity risk
Concurrent use of lithium may increase lithium toxicity
Cyclosporine and tacrolimus may potentiate nephrotoxicity when combined with valsartan/hydrochlorothiazide
Digoxin levels may be altered, requiring monitoring when co-administered
Co-administration with rifampin, rifabutin, or rifapentine may reduce valsartan effectiveness
Methotrexate clearance can be impaired, increasing risk of toxicity
Concurrent use with diuretics may exacerbate volume depletion and electrolyte imbalances
Combination with other blood pressure lowering agents may cause additive hypotensive effects
Opioid pain medicines, muscle relaxants, sleeping pills may enhance CNS depression when combined
Colestyramine or colestipol should be administered 4 hours apart to avoid absorption interference
Concurrent use with cancer chemotherapy agents like cyclophosphamide may require close monitoring
Oral diabetes medications and insulin efficacy may be affected, requiring dose adjustment
Ritonavir and other protease inhibitors may affect valsartan metabolism
Herbal supplements such as licorice root may counteract antihypertensive effects or increase potassium loss

Preparations Of The Drug

Fixed dose combination oral tablets for hypertension treatment available as Diovan HCT
Dosage strengths include 12.5 mg hydrochlorothiazide combined with 80 mg, 160 mg, or 320 mg valsartan
Higher hydrochlorothiazide combinations include 25 mg with 160 mg or 320 mg valsartan for titration
Tablets designed for once-daily dosing to enhance compliance
Supplied for oral use with instructions for administration regardless of food intake
Available as branded product under Diovan HCT with standardized manufacturing quality
Includes comprehensive patient information leaflets detailing indications, dosing, and precautions
Packaging to protect tablets from moisture and heat, stored at room temperature
Prescribed with instructions for dose adjustment based on clinical response
Provided in blister packs or bottles depending on manufacturer and prescribing guidelines
Includes identifiers and labeling to differentiate among dosage strengths
Not available as generics in fixed-dose combinations with this exact composition, though components are individually generic
May be supplied with risk management documentation due to pregnancy contraindications
Distributed through prescription-only channels ensuring professional oversight
Provision for patient support resources and professional prescribing information